Anus neoplasm

This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…

This study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…

This study looks at whether irreversible electroporation (IRE) can safely and effectively treat recurrent pelvic tumors in people who cannot have surgery, radiation, or other local treatments. IRE uses electrical pulses to destroy cancer cells without cutting or heating tissue. R…

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…

This study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an adde…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can improve outcomes for people with early-stage anal cancer. About 23 participants will receive the combination treatment, followed by maintenance therapy. The main goal i…

This phase 3 trial tests whether the immunotherapy drug sintilimab can replace the chemotherapy drug mitomycin in standard chemoradiation for limited-stage anal squamous cell carcinoma. About 350 patients who have not yet been treated will receive either the standard regimen (rad…

This phase 2 trial tests a new way to deliver radiation therapy for anal cancer using MRI guidance to adjust doses based on each patient's risk level. About 80 adults with anal squamous cell carcinoma will receive different radiation schedules depending on their tumor risk group.…

This study tests whether a single infusion of a patient's own genetically engineered immune cells (E7 TCR-T cells) can shrink or eliminate HPV-related cancers before the patient receives standard treatment like chemo-radiation or surgery. The trial enrolls 15 adults with advanced…

This study tests a new immunotherapy for people with advanced HPV-related cancers, such as cervical, throat, anal, and penile cancers. Participants receive specially engineered immune cells designed to attack cancer cells carrying the HPV16 virus. The goal is to see if this treat…

This study tests whether adding an immunotherapy drug (anti-PD-1) to standard chemoradiation can better control anal squamous cell cancer and reduce the chance of it coming back. It includes 241 adults aged 18-75 with different stages of the disease, from early to advanced or rec…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This pilot study tests whether using artificial intelligence to adjust radiation plans daily can better target tumors while sparing healthy organs in people with locally advanced anal cancer. Twenty participants will receive standard radiation over six weeks, but each day's plan …

This program provides retifanlimab, an immunotherapy drug, together with standard chemotherapy (carboplatin and paclitaxel) to adults with advanced squamous cell carcinoma of the anal canal who cannot join other clinical trials. The goal is to offer a potential treatment option w…

This study tests a new drug called LCB84, which targets a protein (TROP2) found on many cancer cells and delivers a toxic payload directly to them. It is being tested alone and together with an immunotherapy drug (anti-PD-1) in 300 people with advanced solid tumors that have not …

This phase 3 trial tests whether giving a specific chemotherapy combination (mDCF) before standard chemoradiotherapy can improve outcomes for people with locally advanced anal cancer. About 310 adults with stage T3-4 or N1 anal cancer will be randomly assigned to either standard …

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This phase 2 trial tests whether a vaginal DHEA suppository can safely improve vaginal health in 25 women who had radiation for gynecologic, anal, or rectal cancer. Radiation often causes dryness, burning, and pain, similar to menopause. DHEA is a hormone replacement that may hel…

This study is for women with anal cancer who need pelvic radiation. It tests whether using a vaginal dilator during each radiation session can reduce the risk of vaginal narrowing (stenosis) after treatment. Half of the 60 participants will use the dilator during radiation, and t…

This study tests whether using virtual reality (VR) can reduce severe belly pain and improve quality of life in people with digestive tract cancers. 360 participants will be split into three groups: one using a skills-based VR program, one using distracting VR videos, and a contr…

This study tests a nerve block called ganglion impar neurolysis to see if it can reduce pain caused by radiation therapy for anal cancer. Five adults with localized anal cancer who are getting chemotherapy and radiation will receive the nerve block. Researchers will track pain sc…

This study is for Black adults newly diagnosed with gastrointestinal cancer. It focuses on ensuring patients receive proper biomarker testing and evidence-based care, helping them find and join clinical trials if they choose, and providing easy-to-understand information about the…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…

This study looks at whether letting people collect their own anal samples at home can increase the number of high-risk individuals who follow through with clinic appointments for anal cancer screening. About 572 participants from Chicago, Houston, and Milwaukee will either self-s…

This study looks at anal cancer risk in men who have sex with men (MSM) who take PrEP to prevent HIV. Researchers want to find out how common high-grade anal lesions are, how well anal swabs detect them, and how these lesions affect quality of life. About 296 participants will an…

This study looks at whether a blood test can detect HPV DNA in people with HPV-related anal or cervical cancer who are receiving radiation therapy. Researchers will collect blood samples before, during, and after treatment to see if the virus's genetic material shows up and if it…

This study aims to understand which types of HPV are linked to anal cancer in China and how common the disease is. Researchers will collect samples and health data from 300 patients across multiple hospitals. The goal is to learn more about the virus and disease patterns, not to …

This observational study follows 80 women treated with chemoradiotherapy for anal cancer to understand how radiation affects their vaginal and sexual health. Participants will have a gynecological exam, complete questionnaires about quality of life and sexual health, and allow re…

This study follows up with 100 men who took part in the ANRS IPERGAY HIV prevention trial to see how many have developed high-grade anal lesions or anal cancer a decade later. Researchers will use a special test to look for HPV mutations and viral DNA integration in the body. The…

This study will collect blood and tumor samples from 1,100 people with various cancers, including head and neck, ovarian, cervical, lung, and brain cancers. Researchers want to learn how immune cells called T cells behave in these tumors. The goal is to better understand why some…